Rajiv Naval-Srinivas, MD
Internal Medicine · Manchester, KYNPI 1326122904
Payments from drug & device makers
Across 228 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$816
- Novo Nordisk$346
- AstraZeneca$338
- GSK$284
- Merck$274
- Astellas Pharma US Inc$245
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,46893%
- Education$2627%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $816 |
| Novo Nordisk | 27 | $346 |
| AstraZeneca | 17 | $338 |
| GSK | 21 | $284 |
| Merck | 16 | $274 |
| Astellas Pharma US Inc | 6 | $245 |
| Lilly USA, LLC | 23 | $241 |
| Bayer | 8 | $151 |
| Medtronic | 7 | $141 |
| Intuitive Surgical | 1 | $125 |
| Pfizer | 8 | $112 |
| Sunovion Pharmaceuticals Inc. | 5 | $75 |
| Amgen(2 entities) | 4 | $67 |
| Insmed, Inc. | 3 | $65 |
| Amarin Pharma, Inc. | 4 | $58 |
| Boehringer Ingelheim | 3 | $52 |
| Paratek Pharmaceuticals, Inc. | 1 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Ardelyx, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $35 |
| Novartis | 2 | $34 |
| Radius Health, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 2 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$125
- FARXIGA$103
How this compares
$3,729 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 474 | $288,926 |
| MounjaroTirzepatide | 203 | $227,740 |
| JardianceEmpagliflozin | 277 | $214,527 |
| OzempicSemaglutide | 160 | $178,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 162 | $125,994 |
| FarxigaDapagliflozin Propanediol | 143 | $117,854 |
| LinzessLinaclotide | 130 | $87,995 |
| XifaxanRifaximin | 22 | $67,949 |
| Tresiba Flextouch U-100Insulin Degludec | 92 | $66,920 |
| EntrestoSacubitril/Valsartan | 132 | $65,026 |
| TradjentaLinagliptin | 100 | $63,927 |
| Spiriva RespimatTiotropium Bromide | 100 | $57,897 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $44,573 |
| XareltoRivaroxaban | 52 | $40,012 |
| JanuviaSitagliptin Phosphate | 53 | $39,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $52 | $336,351477 claims |
| PfizerEliquis, Nurtec Odt | $112 | $301,197486 claims |
| Lilly USA, LLCMounjaro, Trulicity | $241 | $247,245224 claims |
| Novo NordiskOzempic | $346 | $178,304160 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $338 | $153,218205 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $284 | $137,396188 claims |
| AbbVieLinzess, Vraylar | $816 | $122,366155 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $50 | $67,94922 claims |
| NovartisEntresto | $34 | $65,026132 claims |
| Johnson & JohnsonXarelto | $11 | $40,01252 claims |
| MerckJanuvia | $274 | $39,87653 claims |
| AmgenProlia, Corlanor | $67 | $31,70527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Manchester
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.